Display options
Cite
Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010;3(6):349-57doi: 10.1177/1756283X10377126.
Walters, J. R., & Pattni, S. S. (2010). Managing bile acid diarrhoea. Therapeutic advances in gastroenterology, 3(6), 349-57. https://doi.org/10.1177/1756283X10377126
Walters, Julian R F, and Pattni, Sanjeev S. "Managing bile acid diarrhoea." Therapeutic advances in gastroenterology vol. 3,6 (2010): 349-57. doi: https://doi.org/10.1177/1756283X10377126
Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol. 2010 Nov;3(6):349-57. doi: 10.1177/1756283X10377126. PMID: 21180614; PMCID: PMC3002596.
Copy Download .nbib Format: NLM
Share it on

Therap Adv Gastroenterol. 2010 Nov;3(6):349-57. doi: 10.1177/1756283X10377126.

Managing bile acid diarrhoea.

Therapeutic advances in gastroenterology

Julian R F Walters, Sanjeev S Pattni

Affiliations

  1. Section of Hepatology and Gastroenterology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK.

PMID: 21180614 PMCID: PMC3002596 DOI: 10.1177/1756283X10377126

Abstract

Bowel symptoms including diarrhoea can be produced when excess bile acids (BA) are present in the colon. This condition, known as bile acid or bile salt malabsorption, has been under recognized, as the best diagnostic method, the (75)Se-homocholic acid taurine (SeHCAT) test, is not available in many countries and is not fully utilized in others. Reduced SeHCAT retention establishes that this is a complication of many other gastrointestinal diseases. Repeated studies show SeHCAT tests are abnormal in about 30% of patients otherwise diagnosed as diarrhoea-predominant irritable bowel syndrome or functional diarrhoea, with an estimated population prevalence of around 1%. Recent work suggests that the condition previously called idiopathic bile acid malabsorption (BAM) is not in fact due to a defect in absorption, but results from an overproduction of BA because of defective feedback inhibition of hepatic bile acid synthesis, a function of the ileal hormone fibroblast growth factor 19 (FGF19). The approach to treatment currently depends on binding excess BA, to reduce their secretory actions, using colestyramine, colestipol and, most recently, colesevelam. Colesevelam has a number of potential advantages that merit further investigation in trials directed at patients with bile acid diarrhoea.

Keywords: Crohn's disease; SeHCAT; bile acids; colesevelam; colestipol; colestyramine; fibroblast growth factor 19; functional diarrhoea; irritable bowel syndrome; malabsorption

References

  1. Postgrad Med J. 1992 Apr;68(798):272-6 - PubMed
  2. Eur J Gastroenterol Hepatol. 1996 Feb;8(2):117-23 - PubMed
  3. Aliment Pharmacol Ther. 2009 Oct;30(7):707-17 - PubMed
  4. Am J Gastroenterol. 2010 Apr;105(4):775-85 - PubMed
  5. Eur J Gastroenterol Hepatol. 2008 May;20(5):413-22 - PubMed
  6. Lancet Oncol. 2007 Nov;8(11):1007-17 - PubMed
  7. Gut. 2000 Feb;46(2):170-5 - PubMed
  8. Hepatology. 2009 May;49(5):1403-18 - PubMed
  9. J Lipid Res. 2007 Dec;48(12):2693-700 - PubMed
  10. Gut. 1987 Aug;28(8):970-5 - PubMed
  11. Scand J Gastroenterol Suppl. 1992;194:66-70 - PubMed
  12. Aliment Pharmacol Ther. 1998 Sep;12(9):839-44 - PubMed
  13. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3920-5 - PubMed
  14. Clin Med (Lond). 2010 Apr;10(2):124-6 - PubMed
  15. Neurogastroenterol Motil. 2009 Jul;21(7):734-e43 - PubMed
  16. J R Coll Physicians Lond. 1997 Jan-Feb;31(1):53-6 - PubMed
  17. Acta Physiol (Oxf). 2009 Oct;197(2):129-37 - PubMed
  18. Gut. 1976 Dec;17(12):965-70 - PubMed
  19. J Clin Invest. 1997 Apr 15;99(8):1880-7 - PubMed
  20. Arch Intern Med. 1999 Sep 13;159(16):1893-900 - PubMed
  21. J Nucl Med. 1981 Aug;22(8):720-5 - PubMed
  22. Dig Dis Sci. 1999 Jan;44(1):14-9 - PubMed
  23. Cell Metab. 2005 Oct;2(4):217-25 - PubMed
  24. Scand J Gastroenterol. 1999 Jun;34(6):587-90 - PubMed
  25. Gut. 1991 May;32(5):500-3 - PubMed
  26. Scand J Gastroenterol. 1993 Oct;28(10):865-8 - PubMed
  27. J R Coll Physicians Lond. 2000 Sep-Oct;34(5):448-51 - PubMed
  28. Clin Gastroenterol Hepatol. 2010 Feb;8(2):159-65 - PubMed
  29. Lancet. 1977 Dec 10;2(8050):1193-5 - PubMed
  30. Am J Gastroenterol. 2004 Apr;99(4):711-8 - PubMed
  31. J Intern Med. 2006 Dec;260(6):530-6 - PubMed
  32. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):397-403 - PubMed
  33. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1189-94 - PubMed
  34. Dig Dis Sci. 2001 Oct;46(10):2231-8 - PubMed
  35. Gastroenterology. 1967 Apr;52(4):752-7 - PubMed
  36. Gut. 1991 Oct;32(10):1180-7 - PubMed
  37. Eur J Gastroenterol Hepatol. 2000 May;12(5):541-7 - PubMed
  38. Dan Med Bull. 1973 Dec;20(6):174-7 - PubMed
  39. Curr Treat Options Gastroenterol. 2007 Feb;10(1):28-33 - PubMed
  40. Br Med J (Clin Res Ed). 1985 May 4;290(6478):1315-8 - PubMed
  41. Scand J Gastroenterol. 2003 Aug;38(8):826-30 - PubMed
  42. Clin Gastroenterol. 1986 Jul;15(3):567-82 - PubMed
  43. Expert Rev Gastroenterol Hepatol. 2009 Oct;3(5):461-4 - PubMed
  44. Gut. 1991 Sep;32(9):1004-6 - PubMed
  45. Gut. 2005 Mar;54(3):441-2 - PubMed
  46. World J Gastroenterol. 2006 Dec 21;12(47):7710-4 - PubMed
  47. N Engl J Med. 1969 Aug 21;281(8):397-402 - PubMed
  48. Scand J Gastroenterol. 2001 Oct;36(10):1077-80 - PubMed
  49. Gut. 2004 Jan;53(1):78-84 - PubMed
  50. Br Med J (Clin Res Ed). 1985 Mar 2;290(6469):665-8 - PubMed
  51. Digestion. 2004;69(4):211-8 - PubMed
  52. Br Med Bull. 2009;92:79-93 - PubMed
  53. Am J Manag Care. 1999 Apr;5(4):437-44 - PubMed
  54. Aliment Pharmacol Ther. 2006 Dec;24(11-12):1643-9 - PubMed

Publication Types